Lung cancer is the leading cause of death in individuals with malignant disease.
studies. 8, 9 In addition to lung cancer, baicalein also inhibits the growth and metastasis of prostate cancer cells, 10 the invasion of gastric cancer cells, 11 the migration, adhesion and invasion of breast cancer cells, 12 and induces apoptosis and autophagy in hepatocellular carcinoma cells. 13, 14 In addition, some studies have demonstrated the effects of baicalein on cisplatin sensitivity via different pathways in various cancer cells. [15] [16] [17] Baicalein has also exhibited a wide range of anti-inflammatory effects associated with airway injury, liver injury and rheumatoid arthritis. [18] [19] [20] In summary, baicalein has the potential to become an ideal adjuvant therapy in the treatment of cancer.
Previous studies of baicalein have identified several pathways, such as the ROS/AMPK pathway in lung cancer, 21 the caveolin-1/Akt/mTOR pathway in prostate cancer, 10 the p38 signalling pathway, 11 the PTEN/ Akt/HIF-1a signalling pathway 22 in gastric cancer, the NF-jB signalling pathway in ovarian cancer, 23 the Wnt/b-catenin pathway in breast cancer, 24 the PI3K/Akt pathway in oesophageal squamous cell carcinoma 25 and the ERK pathway in hepatocellular carcinoma. 26 Phosphatase and tensin homolog (PTEN) is known as a tumour suppressor gene that has been reported to affect cancer cell behaviour in various cancers. [27] [28] [29] [30] PTEN may inhibit cellular proliferation, growth and survival through the PI3K/Akt/mTOR pathway. 31, 32 There is also evidence that baicalein may exert its effects via the PTEN/Akt pathway. 22, 33 MicroRNAs (miRNAs) are small non-coding RNAs with lengths of [19] [20] [21] [22] [23] [24] [25] nucleotides that regulate the translation or degradation of target mRNA in the human body. 34 MiRNAs play an important role in the proliferation, invasion and apoptosis of malignant tumour cells and may affect resistance to cisplatin. [35] [36] [37] In addition, pathways that link PTEN and miRNAs exist in cancers. [38] [39] [40] [41] In this study, we assessed the effects of baicalein on proliferation, apoptosis and cisplatin sensitivity in NSCLC A549 and H460 cell lines. We also determined changes in miRNA expression caused by baicalein treatment using the miRNA microarray and validated the hypothesis that baicalein affects the miRNA-PTEN/PI3K/Akt pathway. Our study indicated that baicalein may inhibit cell growth and increase cisplatin sensitivity to A549 and H460 cells by downregulating miR-424-3p and targeting the PTEN/PI3K/Akt pathway.
| MATERIALS AND METHODS

| Cells and reagents
Non-small-cell lung cancer A549 and H460 cell lines and the normal human bronchial epithelial (NHBE) cell line were purchased from the 
| Cell transfection
The miR-424-3p mimics, miR-424-3p inhibitor, miR-scramble or si-PTEN (Shanghai GenePharma Co., Ltd., Shanghai, China) were transfected, or cotransfected, into cells according to the experimental design. When cell confluence was approximately 50%-70%, the medium was replaced with serum-free medium, and transfection was performed in 6-well plates (Corning, Corning, NY, USA) using Lipo- 
| Cell counting kit-8 assay
The cell counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan) assay was used to examine the viability of cells following different treatments. Cells were seeded in a 96-well plate (100 lL) at a density of acetic acid, and then stained with 1% crystal violet (Solarbio, Beijing, China). The number of colonies containing more than 50 cells was determined using an optical microscope (Olympus, Tokyo, Japan).
| Cell apoptosis assays
The Annexin V-FITC/PI Apoptosis Detection Kit (Solarbio, Beijing, China) was used to detect apoptotic cells. Cells were collected 24 hours after treatment, washed with PBS (Solarbio, Beijing, China) and resuspended in binding buffer (500 lL) in an Eppendorf (EP)
tube. Annexin V-FITC and PI (5 lL) were added into binding buffer.
After mixing, the EP tube was kept away from light for 5-15 minutes at room temperature. Flow cytometry (BD, San Diego, CA, USA) was used to identify cells of normal status, early apoptosis, late apoptosis and death; FITC was detected using channel FL1, and PI was detected using channel FL3.
Caspase-3/7 activity was measured using the Apo-ONE â Homo- 
| Animal experiment
| Statistical analysis
Each experiment was repeated three times. Statistical analysis was performed with SPSS 21 software, and data were expressed as mean AE standard deviation (S.D.). One-way ANOVA was carried out to compare three or more groups; Student's t test was used to compare two independent groups. The IC50 of cisplatin was calculated using the normal probability conversion method and probit regression analysis. A P-value of <.05 was considered statistically significant. Figure 3A and Table 1, 33 miRNAs were differentially expressed, with a greater than twofold change in cells treated with 40 lmol/L baicalein as compared to DMSO controls (P < .05). Of the 33 differentially expressed miRNAs, 24 were down-regulated and 9 were up-regulated. Interestingly, the microarray results indicated that miR-424-3p was significantly downregulated, with a greater than fivefold change.
To validate the data obtained from the miRNA microarray, we examined three of the differentially expressed miRNAs in NSCLC confirmed that the microarray data were reliable and that miR-424-3p was down-regulated by baicalein treatment.
| PTEN was identified as a target gene of miR-
424-3p
We suggested that miR-424-3p may mediate the effects of baicalein on the PTEN pathway according to the above results. Thus, we predicted the putative targets to explore probable biological functions of miR-424-3p using prediction software. A complementary pairing area 
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